COVID-19 Vaccine (inactivated, adjuvanted) Valneva

RSS

Withdrawn

This medicine's authorisation has been withdrawn

COVID-19 vaccine (inactivated, adjuvanted, adsorbed)
MedicineHumanWithdrawn

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Rolling review
  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 12 October 2023, the European Commission withdrew the marketing authorisation for COVID-19 Vaccine (inactivated, adjuvanted) Valneva (SARS-CoV-2 virus, strain Wuhan hCoV-19/Italy/INMI1- isl/2020, inactivated) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Valneva Austria GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

COVID-19 Vaccine (inactivated, adjuvanted) Valneva was granted marketing authorisation in the EU on 24 June 2022 for active immunisation against coronavirus disease 2019 (COVID-19). The marketing authorisation was initially valid for a 5-year period. 

The European Public Assessment Report (EPAR) for COVID-19 Vaccine (inactivated, adjuvanted) Valneva is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (412.12 KB - PDF)

Amharc

español (ES) (296.05 KB - PDF)

Amharc

čeština (CS) (353.49 KB - PDF)

Amharc

dansk (DA) (280.97 KB - PDF)

Amharc

Deutsch (DE) (314.28 KB - PDF)

Amharc

eesti (ET) (273.24 KB - PDF)

Amharc

ελληνικά (EL) (416.76 KB - PDF)

Amharc

français (FR) (301.09 KB - PDF)

Amharc

hrvatski (HR) (340.66 KB - PDF)

Amharc

italiano (IT) (285.18 KB - PDF)

Amharc

latviešu (LV) (359.53 KB - PDF)

Amharc

lietuvių (LT) (343.51 KB - PDF)

Amharc

magyar (HU) (327.46 KB - PDF)

Amharc

Malti (MT) (397.24 KB - PDF)

Amharc

Nederlands (NL) (302.98 KB - PDF)

Amharc

polski (PL) (353.81 KB - PDF)

Amharc

português (PT) (293.01 KB - PDF)

Amharc

română (RO) (360.97 KB - PDF)

Amharc

slovenčina (SK) (371.58 KB - PDF)

Amharc

slovenščina (SL) (329.43 KB - PDF)

Amharc

suomi (FI) (277.49 KB - PDF)

Amharc

svenska (SV) (281.18 KB - PDF)

Amharc

Product information

български (BG) (1.39 MB - PDF)

Amharc

español (ES) (1.1 MB - PDF)

Amharc

čeština (CS) (1.19 MB - PDF)

Amharc

dansk (DA) (1.01 MB - PDF)

Amharc

Deutsch (DE) (1.08 MB - PDF)

Amharc

eesti (ET) (974.37 KB - PDF)

Amharc

ελληνικά (EL) (1.46 MB - PDF)

Amharc

français (FR) (1.04 MB - PDF)

Amharc

hrvatski (HR) (1.15 MB - PDF)

Amharc

italiano (IT) (1.09 MB - PDF)

Amharc

latviešu (LV) (1.27 MB - PDF)

Amharc

lietuvių (LT) (1.23 MB - PDF)

Amharc

magyar (HU) (1.2 MB - PDF)

Amharc

Nederlands (NL) (1.08 MB - PDF)

Amharc

polski (PL) (1.27 MB - PDF)

Amharc

português (PT) (1.02 MB - PDF)

Amharc

română (RO) (1.3 MB - PDF)

Amharc

slovenčina (SK) (1.21 MB - PDF)

Amharc

slovenščina (SL) (1.18 MB - PDF)

Amharc

suomi (FI) (1.03 MB - PDF)

Amharc

svenska (SV) (982.29 KB - PDF)

Amharc

norsk (NO) (991.74 KB - PDF)

Amharc
Latest procedure affecting product information:II/0004
12/10/2023
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (144.11 KB - PDF)

Amharc

español (ES) (121.79 KB - PDF)

Amharc

čeština (CS) (126.11 KB - PDF)

Amharc

dansk (DA) (119.05 KB - PDF)

Amharc

Deutsch (DE) (123.25 KB - PDF)

Amharc

eesti (ET) (116.88 KB - PDF)

Amharc

ελληνικά (EL) (134.61 KB - PDF)

Amharc

français (FR) (124.6 KB - PDF)

Amharc

hrvatski (HR) (122.34 KB - PDF)

Amharc

italiano (IT) (120.11 KB - PDF)

Amharc

latviešu (LV) (123.85 KB - PDF)

Amharc

lietuvių (LT) (123.75 KB - PDF)

Amharc

magyar (HU) (121.79 KB - PDF)

Amharc

Malti (MT) (134.68 KB - PDF)

Amharc

Nederlands (NL) (120.28 KB - PDF)

Amharc

polski (PL) (137.11 KB - PDF)

Amharc

português (PT) (124.04 KB - PDF)

Amharc

română (RO) (123.01 KB - PDF)

Amharc

slovenčina (SK) (125.73 KB - PDF)

Amharc

slovenščina (SL) (124.15 KB - PDF)

Amharc

suomi (FI) (114.96 KB - PDF)

Amharc

svenska (SV) (117.48 KB - PDF)

Amharc

Íslenska (IS) (131.46 KB - PDF)

Amharc

norsk (NO) (129.29 KB - PDF)

Amharc

Product details

Name of medicine
COVID-19 Vaccine (inactivated, adjuvanted) Valneva
Active substance
COVID-19 vaccine (inactivated, adjuvanted, adsorbed)
International non-proprietary name (INN) or common name
COVID-19 vaccine (inactivated, adjuvanted, adsorbed)
Therapeutic area (MeSH)
COVID-19 virus infection
Anatomical therapeutic chemical (ATC) code
J07BX03

Pharmacotherapeutic group

Vaccines

Therapeutic indication

COVID-19 Vaccine (inactivated, adjuvanted) Valneva is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 to 50 years of age. 

The use of this vaccine should be in accordance with official recommendations.

Authorisation details

EMA product number
EMEA/H/C/006019
Marketing authorisation holder
Valneva Austria GmbH

Campus Vienna Biocenter 3
Landstrasse
A-1030 Vienna
Austria

Opinion adopted
23/06/2022
Marketing authorisation issued
24/06/2022
Withdrawal of marketing authorisation
12/10/2023
Revision
6

Assessment history

Safety updates

This page was last updated on

Share this page